<DOC>
	<DOCNO>NCT00897845</DOCNO>
	<brief_summary>RATIONALE : Studying sample tumor tissue patient cancer laboratory may help doctor learn change occur DNA identify biomarkers related cancer . PURPOSE : This research study look tumor sample woman undergone chemotherapy breast cancer .</brief_summary>
	<brief_title>Studying Tumor Samples From Women Who Have Undergone Chemotherapy Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - To identify gene set risk recurrence use molecular profiling sample woman lymph node-positive high-risk lymph node-negative breast cancer clinical trial ECOG-E2197 . Secondary - To define set significant gene prognostic marker recurrence . - To compare prognostic value Oncotype DX™ ( ODX ) 21 gene assay clinical trial gene set determine study . - To compare DASL™ assay ODX 21 gene ODX assay result clinical trial . - To compare prognostic value select gene gene set determine study . OUTLINE : This multicenter study . Samples use molecular profile apply custom panel breast cancer-related gene cDNA-mediated Annealing , Selection , Extension , Ligation ( DASL™ ) assay , immunohistochemistry , study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm breast cancer tumor sample collect clinical trial ECOGE2197 Histologically lymph nodepositive ( N13 ) OR highrisk lymph nodenegative disease Hormone receptorpositive negative disease ( status know ) HER2 status know PATIENT CHARACTERISTICS : Menopausal status specify PRIOR CONCURRENT THERAPY : See Disease Characteristics</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
</DOC>